Mesoblast (NASDAQ:MESO) Shares Gap Down - Should You Sell?

Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s share price gapped down prior to trading on Friday . The stock had previously closed at $11.32, but opened at $10.50. Mesoblast shares last traded at $10.33, with a volume of 83,418 shares changing hands.

Analysts Set New Price Targets

MESO has been the subject of a number of recent research reports. Cantor Fitzgerald reissued an "overweight" rating on shares of Mesoblast in a research note on Thursday, August 29th. Maxim Group raised Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 price target on the stock in a research note on Tuesday, September 24th. StockNews.com downgraded Mesoblast from a "hold" rating to a "sell" rating in a report on Wednesday, September 4th. Piper Sandler upgraded Mesoblast from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $4.00 to $11.00 in a report on Tuesday, July 23rd. Finally, Jefferies Financial Group raised Mesoblast from a "hold" rating to a "buy" rating in a research note on Thursday, August 29th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $11.50.

Mesoblast Stock Performance

The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The company has a fifty day simple moving average of $8.54 and a two-hundred day simple moving average of $7.59.

Institutional Trading of Mesoblast

A number of large investors have recently bought and sold shares of the business. Marshall Wace LLP acquired a new position in shares of Mesoblast in the second quarter valued at approximately $562,000. XY Capital Ltd bought a new stake in Mesoblast in the 3rd quarter valued at $244,000. Jane Street Group LLC boosted its stake in Mesoblast by 46.4% in the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company's stock worth $695,000 after purchasing an additional 26,959 shares during the period. Creative Planning bought a new position in Mesoblast during the 3rd quarter worth about $147,000. Finally, XTX Topco Ltd bought a new position in Mesoblast during the 2nd quarter worth about $103,000. 1.43% of the stock is owned by institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.